CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Bupivacaine +1 moredrug
Likely dose
Bupivacaine 10mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01632709
NCT01632709Phase 4Completed
CompareCT.gov

Pathophysiology of Post Amputation Pain

Shirley Ryan AbilityLab·interventional·Posted Jul 3, 2012·Updated Jul 21, 2015

In Brief

A Phase 4 clinical trial evaluating Bupivacaine and Placebo for Amputation Stumps and Neuroma. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to see how Post Amputation Pain (PAP) affects the body and brain by using sensory testing (such as pinprick testing), taking pictures of your brain (using a functional magnetic resonance imaging (fMRI) machine) and biomedical interventions (such as an injection of pain medicine). All medicines and the fMRI machine used during this study are FDA approved. The investigators hope that by learning the causes of PAP, the investigators can help future amputees.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmputation Stumps, Neuroma
CountriesUnited States
CollaboratorsUnited States Department of Defense, Northwestern University

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 3, 2012
Enrollment StartMay 1, 2012
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 14.0 years ago

Interventions

Bupivacainedrug

one injection of 10ml of .25%

Placebodrug

Dry needling